AqueSys develops, manufactures and commercializes the XEN Gel Stent technology to treat glaucoma. The company is led by President and CEO Ron Bache and is based in Aliso Viejo, California. At the time of the report it had completed enrollment of its first FDA IDE study and begun enrollment of a second FDA‑approved IDE study using an additional XEN Gel Stent model. AqueSys had also initiated focused international commercialization. The company secured new funding to support continued development and commercialization of its XEN Gel Stent. AqueSys, Inc. is an Irvine, California-based medical device company that develops, manufactures and distributes proprietary implants for glaucoma. Its flagship implant offers a 10-minute non-invasive surgical treatment intended to halt glaucoma-related vision loss. The company is focused on advancing clinical development and obtaining regulatory approvals to commercialize its implant. It both manufactures and distributes the devices, indicating an established supply and go-to-market capability. A recent $35m Series C financing positions the company to pursue its clinical, regulatory and commercial objectives. Existing investors including Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences continue to back the company.

Total raised

$79M

Funding rounds

2

Latest round

Series D

Latest activity

Jan 2014